DD286107A5 - Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt - Google Patents

Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt Download PDF

Info

Publication number: DD286107A5
Authority: DD; German Democratic Republic
Prior art keywords: dopa; core; coated; composition; produces
Prior art date: 1986-08-26

Application number

DD87306327A

Other languages

German (de)

English (en)

Inventor

Curt H Appelgren

Eva Ch Eskilsson

Original Assignee

��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-26

Filing date

1987-08-25

Publication date

1991-01-17

1987-08-25 Application filed by ��@��@��k�� filed Critical ��@��@��k��

1991-01-17 Publication of DD286107A5 publication Critical patent/DD286107A5/de

Links

239000000203 mixture Substances 0.000 title claims abstract description 44
150000001875 compounds Chemical class 0.000 title claims abstract description 7
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 49
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 48
210000004051 gastric juice Anatomy 0.000 claims abstract description 8
239000008363 phosphate buffer Substances 0.000 claims abstract description 7
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 20
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 20
238000000034 method Methods 0.000 claims description 10
239000001856 Ethyl cellulose Substances 0.000 claims description 8
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
235000019325 ethyl cellulose Nutrition 0.000 claims description 8
229920001249 ethyl cellulose Polymers 0.000 claims description 8
102000004190 Enzymes Human genes 0.000 claims description 5
108090000790 Enzymes Proteins 0.000 claims description 5
229920006318 anionic polymer Polymers 0.000 claims description 4
239000003954 decarboxylase inhibitor Substances 0.000 claims description 4
229940123736 Decarboxylase inhibitor Drugs 0.000 claims description 3
229960004205 carbidopa Drugs 0.000 claims description 3
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 2
229920003141 Eudragit® S 100 Polymers 0.000 claims 1
230000036470 plasma concentration Effects 0.000 abstract description 9
208000018737 Parkinson disease Diseases 0.000 abstract description 5
231100000957 no side effect Toxicity 0.000 abstract 1
239000008187 granular material Substances 0.000 description 22
239000002775 capsule Substances 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000000694 effects Effects 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229920003134 Eudragit® polymer Polymers 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
230000037058 blood plasma level Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
-1 methyl methacrylate methyl ester Chemical class 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
PJHUABJTDFXYRQ-UHFFFAOYSA-N benzoyl azide Chemical compound [N-]=[N+]=NC(=O)C1=CC=CC=C1 PJHUABJTDFXYRQ-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
YYJWBYNQJLBIGS-UHFFFAOYSA-N methyl 2-methylbut-2-enoate Chemical class COC(=O)C(C)=CC YYJWBYNQJLBIGS-UHFFFAOYSA-N 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Detergent Compositions (AREA)
Fats And Perfumes (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DD87306327A 1986-08-26 1987-08-25 Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt DD286107A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8603582A SE460947B (sv)	1986-08-26	1986-08-26	En multiple-unit-dos komposition av l-dopa

Publications (1)

Publication Number	Publication Date
DD286107A5 true DD286107A5 (de)	1991-01-17

Family

ID=20365397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD87306327A DD286107A5 (de)	1986-08-26	1987-08-25	Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt

Country Status (15)

Country	Link
US (1)	US4981695A (fr)
EP (1)	EP0260236B1 (fr)
JP (1)	JPH0662405B2 (fr)
AT (1)	ATE58292T1 (fr)
CA (1)	CA1298198C (fr)
DD (1)	DD286107A5 (fr)
DE (1)	DE3766200D1 (fr)
DK (1)	DK442287A (fr)
ES (1)	ES2036221T3 (fr)
FI (1)	FI86689C (fr)
HU (1)	HU197211B (fr)
MX (1)	MX172918B (fr)
NO (1)	NO176549C (fr)
PT (1)	PT85591B (fr)
SE (1)	SE460947B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4983400A (en) *	1986-06-16	1991-01-08	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
US4832957A (en) *	1987-12-11	1989-05-23	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
CA2007181C (fr) *	1989-01-06	1998-11-24	Angelo Mario Morella	Compose pharmaceutique a liberation continue
US5202128A (en) *	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
CA2007055A1 (fr) *	1989-01-06	1990-07-06	Garth Boehm	Forme posologique de theophylline
US5196203A (en) *	1989-01-06	1993-03-23	F. H. Faulding & Co. Limited	Theophylline dosage form
DE4101873C2 (de)	1991-01-23	1993-12-09	Isis Pharma Gmbh	Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) *	1994-09-06	1995-12-26	Bristol-Myers Squibb Co.	Gepirone dosage form
US6992107B1 (en)	1995-03-10	2006-01-31	Photocure Asa	Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US6492420B2 (en)	1995-03-10	2002-12-10	Photocure As	Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US7530461B2 (en)	1995-03-10	2009-05-12	Photocure Asa	Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US5997831A (en) *	1996-07-12	1999-12-07	Engelhard Corporation	Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) *	2000-03-10	2005-10-17	Merck Patent Gmbh	(r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en)	2000-07-27	2000-09-13	Photocure Asa	Compounds
PT1408964E (pt) *	2001-07-26	2007-05-31	Merck Patent Gmbh	Utilização de 2-5-(4-fluorofenil) -3-piridilmetilaminometil-cromano e de seus sais fisiologicamente aceitáveis.
EP1490073A4 (fr) *	2002-03-21	2006-02-01	Martin C Hinz	Technologie d'optimisation d'un segment de systeme de serotonine et catecholamine
ITMI20030827A1 (it) *	2003-04-18	2004-10-19	Unihart Corp	Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
KR20060108692A (ko) *	2003-10-31	2006-10-18	알자 코포레이션	메트포르민의 개선된 흡수를 위한 조성물 및 제형
CA2549195A1 (fr) *	2003-12-09	2005-06-23	Spherics, Inc.	Polymeres bioadhesifs a fonction catechol
US20080311191A1 (en) *	2004-08-27	2008-12-18	Avinash Nangia	Multi-Layer Tablets and Bioadhesive Dosage Forms
CA2613631A1 (fr) *	2005-06-23	2007-01-04	Spherics, Inc.	Formes de dosage ameliorees pour le traitement de troubles moteurs
AR055106A1 (es) *	2005-08-05	2007-08-08	Osmotica Pharmaceutical Argent	Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
EP1988887A2 (fr) *	2006-01-13	2008-11-12	University of South Carolina	Méthode et composition pour le traitement de la maladie de parkinson
EP2086515A2 (fr) *	2006-03-02	2009-08-12	Vaunnex, Inc.	Formulations bioadhésives posologiques orales a liberation controlee
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
AU2007338631A1 (en) *	2006-12-22	2008-07-03	Combinatorx, Incorporated	Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1116256A (fr) *	1954-12-09	1956-05-07		Stylographe à bille
DE1128461B (de) *	1959-01-15	1962-04-26	Fernseh Gmbh	Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) *	1970-12-02	1972-07-13	Sobio Lab	Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (fr) *	1973-04-02	1980-05-21
DE2343218C2 (de) *	1973-08-28	1986-08-07	Hoechst Ag, 6230 Frankfurt	Furosemid enthaltende Pellets
DE2513940A1 (de) *	1975-03-29	1976-10-14	Merck Patent Gmbh	Pharmazeutische zubereitung
DE2655331A1 (de) *	1976-12-07	1978-06-08	Hoechst Ag	Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) *	1977-08-29	1979-03-17	Omron Tateisi Electronics Co	Temperature control system for boiler
CH627077A5 (en) *	1978-01-01	1981-12-31	Sankyo Co	Pharmaceutical composition which foams in the intestine
CH649216A5 (de) *	1979-08-16	1985-05-15	Sandoz Ag	Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) *	1980-01-12	1981-07-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) *	1981-09-14	1985-10-31	Hoffmann La Roche	Pharmazeutisches praeparat.
DK150008C (da) *	1981-11-20	1987-05-25	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) *	1982-02-10	1984-05-01	Pack Howard M	Method and composition for reducing weight
JPS59139317A (ja) *	1983-01-31	1984-08-10	Teisan Seiyaku Kk	持続性のニフエジピン製剤
IE56459B1 (en) *	1983-12-21	1991-08-14	Elan Corp Ltd	Controlled absorption pharmaceutical formulation
NZ220599A (en) *	1986-06-16	1990-10-26	Merck & Co Inc	Controlled release oral dosage formulation of carbidopa and levodopa

1986
- 1986-08-26 SE SE8603582A patent/SE460947B/sv not_active IP Right Cessation
1987
- 1987-08-21 ES ES198787850251T patent/ES2036221T3/es not_active Expired - Lifetime
- 1987-08-21 AT AT87850251T patent/ATE58292T1/de not_active IP Right Cessation
- 1987-08-21 DE DE8787850251T patent/DE3766200D1/de not_active Expired - Lifetime
- 1987-08-21 EP EP87850251A patent/EP0260236B1/fr not_active Expired - Lifetime
- 1987-08-25 HU HU873749A patent/HU197211B/hu unknown
- 1987-08-25 MX MX007910A patent/MX172918B/es unknown
- 1987-08-25 NO NO873589A patent/NO176549C/no unknown
- 1987-08-25 DD DD87306327A patent/DD286107A5/de not_active IP Right Cessation
- 1987-08-25 CA CA000545254A patent/CA1298198C/fr not_active Expired - Lifetime
- 1987-08-25 DK DK442287A patent/DK442287A/da not_active Application Discontinuation
- 1987-08-25 FI FI873672A patent/FI86689C/fi not_active IP Right Cessation
- 1987-08-26 JP JP62210363A patent/JPH0662405B2/ja not_active Expired - Lifetime
- 1987-08-26 PT PT85591A patent/PT85591B/pt not_active IP Right Cessation
1989
- 1989-07-12 US US07/378,423 patent/US4981695A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT85591A (en)	1987-09-01
DK442287A (da)	1988-02-27
NO873589L (no)	1988-02-29
ATE58292T1 (de)	1990-11-15
DE3766200D1 (de)	1990-12-20
HU197211B (en)	1989-03-28
EP0260236B1 (fr)	1990-11-14
FI873672L (fi)	1988-02-27
MX172918B (es)	1994-01-21
FI873672A0 (fi)	1987-08-25
EP0260236A1 (fr)	1988-03-16
ES2036221T3 (es)	1993-05-16
NO176549B (no)	1995-01-16
PT85591B (pt)	1990-05-31
SE8603582L (sv)	1988-02-27
SE460947B (sv)	1989-12-11
FI86689B (fi)	1992-06-30
NO176549C (no)	1995-04-26
NO873589D0 (no)	1987-08-25
HUT44438A (en)	1988-03-28
US4981695A (en)	1991-01-01
FI86689C (fi)	1992-10-12
CA1298198C (fr)	1992-03-31
JPH0662405B2 (ja)	1994-08-17
JPS63139128A (ja)	1988-06-10
SE8603582D0 (sv)	1986-08-26
DK442287D0 (da)	1987-08-25

Legal Events

Date	Code	Title	Description
1993-04-01	NPI	Change in the person, name or address of the patentee (addendum to changes before extension act)
2000-01-05	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD286107A5 (de)	1991-01-17	Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt
EP0519870B1 (fr)	1996-09-11	Nouvelle composition à base de diclofenac pour l'administration orale
DE69230112T2 (de)	2000-03-02	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69000881T2 (de)	1993-08-12	2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
EP1207866B1 (fr)	2004-10-13	Forme d'administration a action retardee contenant du saccharinate de tramadol
DE69025208T2 (de)	1996-06-13	Arzneimittel mit verzögerter Freigabe
EP0068191B2 (fr)	1991-09-11	Formes orales du dipyridamole
DE69331806T2 (de)	2003-01-16	Multipartikel-arzneistoffabgabesystem mit stossweiser freisetzung
DE60021749T2 (de)	2006-04-20	Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
DE69430491T2 (de)	2002-08-08	Verfahren zur verkapselung von nsaids
DE69111832T2 (de)	1996-03-14	Naproxen-Formulierung zur kontrollierten Absorption zur einmal täglichen Anwendung.
DE60128215T2 (de)	2008-01-10	Beschichtungszusammensetzung zur geschmacksmaskierung
DE69305335T2 (de)	1997-04-30	Pharmazeutische zubereitung und verfahren für ihre herstellung
DE68909772T2 (de)	1994-05-11	Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
EP1372624B1 (fr)	2005-08-24	Medicament a base de tramadol
DE69429632T2 (de)	2002-11-14	Dosisform mit gesteuerter freigabe für kalium
DE10025946A1 (de)	2001-11-29	Wirkstoffkombination
DE3853341T2 (de)	1995-11-09	Form zur verzögerten Diltiazemfreisetzung sowie das daraus hergestellte Arzneimittel.
DE69216910T2 (de)	1997-05-22	Diltiazem enthaltende Zusammensetzung
DE69619979T2 (de)	2002-11-21	Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
DD298205A5 (de)	1992-02-13	Verfahren zum herstellen von langzeitwirkenden arzneimittelzubereitungen
DE69817848T2 (de)	2005-04-07	Monolithsysteme enthaltend mindestens einer wirkstoff, bestehend aus drei schichten mit unterschiedlichen freisetzungmechanismus
EP0994696B1 (fr)	2004-02-18	Preparations pharmaceutiques a liberation controlee contenant un inhibiteur de l'enzyme de conversion de l'angiotensine comme principe actif
EP0378137A2 (fr)	1990-07-18	Forme galénique
DE10209979A1 (de)	2003-09-25	Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung